Success Metrics

Clinical Success Rate
85.2%

Based on 23 completed trials

Completion Rate
85%(23/27)
Active Trials
5(14%)
Results Posted
61%(14 trials)
Terminated
4(11%)

Phase Distribution

Ph early_phase_1
2
5%
Ph phase_2
14
38%
Ph phase_3
6
16%
Ph phase_4
8
22%
Ph phase_1
3
8%
Ph not_applicable
2
5%

Phase Distribution

5

Early Stage

14

Mid Stage

14

Late Stage

Phase Distribution35 total trials
Early Phase 1First-in-human
2(5.7%)
Phase 1Safety & dosage
3(8.6%)
Phase 2Efficacy & side effects
14(40.0%)
Phase 3Large-scale testing
6(17.1%)
Phase 4Post-market surveillance
8(22.9%)
N/ANon-phased studies
2(5.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.2%

23 of 27 finished

Non-Completion Rate

14.8%

4 ended early

Currently Active

5

trials recruiting

Total Trials

37

all time

Status Distribution
Active(6)
Completed(23)
Terminated(4)
Other(4)

Detailed Status

Completed23
Recruiting5
Terminated4
unknown4
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
37
Active
5
Success Rate
85.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (5.7%)
Phase 13 (8.6%)
Phase 214 (40.0%)
Phase 36 (17.1%)
Phase 48 (22.9%)
N/A2 (5.7%)

Trials by Status

not_yet_recruiting13%
completed2362%
terminated411%
unknown411%
recruiting514%

Recent Activity

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more
NCT07101445Phase 4

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Recruiting
NCT07300735Not Applicable

Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers

Recruiting
NCT07661459Phase 2

Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)

Not Yet Recruiting
NCT04211259Early Phase 1

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Recruiting
NCT05421416Phase 2

Loratadine for the Prevention of G-CSF-related Bone Pain

Recruiting
NCT06019728Phase 4

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

Completed
NCT06955741Phase 1

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

Completed
NCT06531707Phase 3

Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine

Recruiting
NCT05043350Phase 2

Combined Antihistaminics Therapy in COVID 19 Patients

Completed
NCT05750875Phase 4

Gabapentin Versus Loratadine in Uremic Pruritus

Completed
NCT04248712Phase 2

Antihistamines in Eosinophilic Esophagitis

Terminated
NCT02495077Phase 2

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Completed
NCT05243706Phase 3

Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy

Unknown
NCT03855228Phase 3

Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)

Completed
NCT05190627Phase 2

Effect of Loratadine in Lymphangioleiomyomatosis

Unknown
NCT02583594Phase 1

A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

Completed
NCT03883386Phase 2

Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use

Terminated
NCT02478398Phase 3

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Completed
NCT02392039Early Phase 1

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

Terminated
NCT02339714Phase 2

Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
37